Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, revenue was USD 0.107 million compared to USD 0.853 million a year ago. Net loss was USD 71.71 million compared to USD 87.64 million a year ago. Basic loss per share from continuing operations was USD 44.7 compared to USD 55.22 a year ago.